Allopregnanolone

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Allopregnanolone
Accession Number
DB11859
Type
Small Molecule
Groups
Investigational
Description

Allopregnanolone is under investigation for the treatment of Super-Refractory Status Epilepticus. Allopregnanolone has been investigated for the treatment of Severe Postpartum Depression.

Structure
Thumb
Synonyms
Not Available
External IDs
SAGE-547
Categories
UNII
S39XZ5QV8Y
CAS number
516-54-1
Weight
Average: 318.4935
Monoisotopic: 318.255880332
Chemical Formula
C21H34O2
InChI Key
AURFZBICLPNKBZ-SYBPFIFISA-N
InChI
InChI=1S/C21H34O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h14-19,23H,4-12H2,1-3H3/t14-,15+,16-,17+,18-,19-,20-,21+/m0/s1
IUPAC Name
1-[(1S,2S,5R,7S,10R,11S,14S,15S)-5-hydroxy-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-14-yl]ethan-1-one
SMILES
[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](O)CC[C@]12C

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Allopregnanolone.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Allopregnanolone.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Allopregnanolone.
AcetazolamideThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Acetazolamide.
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Allopregnanolone.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Allopregnanolone.
AlaproclateThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Alaproclate.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Allopregnanolone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Allopregnanolone.
AlimemazineThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Alimemazine.
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0001449
KEGG Compound
C13712
PubChem Compound
92786
PubChem Substance
347828198
ChemSpider
83760
BindingDB
50191342
ChEBI
50169
ChEMBL
CHEMBL207538
Wikipedia
Allopregnanolone

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentAlzheimer's Disease (AD) / Mild Cognitive Impairment (MCI)1
1, 2CompletedTreatmentSuper-Refractory Status Epilepticus1
2CompletedTreatmentPostpartum Depression1
2CompletedTreatmentPosttraumatic Epilepsy / Traumatic Brain Injury (TBI)1
2CompletedTreatmentSevere Postpartum Depression1
2CompletedTreatmentTremor, Essential1
2Enrolling by InvitationTreatmentFragile X-Associated Tremor/Ataxia Syndrome1
3CompletedTreatmentModerate Postpartum Depression1
3CompletedTreatmentSevere Postpartum Depression1
3CompletedTreatmentSuper-Refractory Status Epilepticus1
Not AvailableNo Longer AvailableNot AvailableSuper-Refractory Status Epilepticus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00136 mg/mLALOGPS
logP4.28ALOGPS
logP3.99ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)18.3ChemAxon
pKa (Strongest Basic)-1.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area37.3 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity92.91 m3·mol-1ChemAxon
Polarizability38.57 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-MS (1 MEOX; 1 TMS)GC-MSsplash10-0udi-6910000000-837b37f206729753b640
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - GC-MSGC-MSsplash10-0udi-6910000000-837b37f206729753b640
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Pregnane steroids
Direct Parent
Gluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
20-oxosteroids / 3-alpha-hydroxysteroids / Secondary alcohols / Ketones / Cyclic alcohols and derivatives / Organic oxides / Hydrocarbon derivatives
Substituents
Progestogin-skeleton / 20-oxosteroid / 3-hydroxysteroid / Hydroxysteroid / 3-alpha-hydroxysteroid / Oxosteroid / Cyclic alcohol / Ketone / Secondary alcohol / Organooxygen compound
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
3-hydroxy-5alpha-pregnan-20-one (CHEBI:50169) / C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives (LMST02030156)

Drug created on October 20, 2016 14:54 / Updated on October 01, 2018 15:05